Beck Bode LLC Sells 25,409 Shares of Humana Inc. (NYSE:HUM)

Beck Bode LLC lowered its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 97.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 735 shares of the insurance provider's stock after selling 25,409 shares during the period. Beck Bode LLC's holdings in Humana were worth $337,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Auxano Advisors LLC bought a new stake in shares of Humana in the fourth quarter worth $540,000. Mariner LLC boosted its holdings in Humana by 2.3% in the third quarter. Mariner LLC now owns 14,119 shares of the insurance provider's stock worth $6,869,000 after purchasing an additional 312 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Humana by 27.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 27,943 shares of the insurance provider's stock worth $13,595,000 after purchasing an additional 6,034 shares during the period. Silverarc Capital Management LLC acquired a new position in Humana in the third quarter worth $4,865,000. Finally, Vest Financial LLC boosted its holdings in Humana by 43.3% in the fourth quarter. Vest Financial LLC now owns 27,993 shares of the insurance provider's stock worth $12,815,000 after purchasing an additional 8,455 shares during the period. Institutional investors own 92.38% of the company's stock.

Humana Price Performance

Humana stock traded up $12.12 during midday trading on Wednesday, hitting $314.21. The company's stock had a trading volume of 2,426,199 shares, compared to its average volume of 1,998,053. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The stock's 50-day moving average price is $325.28 and its 200-day moving average price is $390.72. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $541.21. The company has a market capitalization of $37.86 billion, a PE ratio of 19.56, a price-to-earnings-growth ratio of 1.76 and a beta of 0.45.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm had revenue of $29.61 billion for the quarter, compared to analysts' expectations of $28.52 billion. During the same period in the previous year, the business earned $9.38 earnings per share. Humana's revenue for the quarter was up 10.7% compared to the same quarter last year. Analysts anticipate that Humana Inc. will post 16.18 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.13%. Humana's payout ratio is presently 22.04%.

Insiders Place Their Bets

In related news, Director Jorge S. Mesquita acquired 545 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.29% of the company's stock.

Analysts Set New Price Targets

HUM has been the subject of a number of research reports. TheStreet downgraded shares of Humana from a "b" rating to a "c+" rating in a report on Monday, January 8th. Truist Financial reissued a "hold" rating and set a $550.00 price target on shares of Humana in a report on Friday, January 19th. TD Cowen reduced their price target on shares of Humana from $427.00 to $396.00 and set a "buy" rating for the company in a report on Tuesday, April 2nd. Oppenheimer reduced their price target on shares of Humana from $415.00 to $370.00 and set an "outperform" rating for the company in a report on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Humana from a "buy" rating to a "hold" rating and reduced their price target for the company from $595.00 to $360.00 in a report on Thursday, January 25th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, Humana currently has an average rating of "Hold" and an average target price of $424.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.